Применение метода ВЭЖХ в изучении фармакокинетики домперидона улиц с различным генотипом
Диссертация
Актуальность. Домперидон, являясь антидопаминергическим препаратом периферического действия, в настоящее время широко используется в РФ при нарушениях моторики желудочно-кишечного тракта. Являясь производным бензимидазола, молекула домперидона липофильна, обладает большой конформационной вариабельностью и имеет большое сродство к транспортному белку Р-гликопротеину. Разработанная методика анализа… Читать ещё >
Список литературы
- А.С. Логинов и др. Мотилиум: эффективность в терапии диспептиче-ских расстройств. // Клиническая фармакология и терапия. 1996. -№ 3. — С. 28.
- Бейтуганова И.М. Рефлюкс индуцированая бронхиальная астма//
- Рус.мед.журн. 1998.-№. 6. — С. 1102 — 1108.
- Белохвостое А.С. ПЦР и лигазные реакции, принципы, традиционные методики и нововведения.// Молекулярная генетика, микробиология и вирусология. 1995 — № 2 — С 21−26.
- Вартепенян А.Б. // Молекул. Биол. 1991 — № 4 — С. 926−936.
- Ктиторова О.В., Какпакова Е. С., Рыбалкина Е. Ю., Захарова Е. С., Ильина Е. Н., Говорун В. М., Логачева Н. П., Иншаков А. Н., Иванов П. К. // Клиническая лабораторная диагностика. 2000.- № 4.
- Минушкин О.Н., Масловский Л. В., Шапошникова О. Ф. Мотилиум в патологии ЖКТ.// Кремлёвская медицина. 1998. — № 2 — С. 35−36.
- Стыскин Е.Л., Ициксон Л. Б., Брауде Е. В. Практическая высокоэффективная жидкостная хроматография. М., 1996. 284 с.
- Тюрина. Автореферат. М., 1998. С. 18.
- Шептулин А.А. Прокинетический препарат мотилиум: фармакологические свойства и возможности клинического применения // Клин, медицина. 1997. — № 11. — С. 48−50.
- Шептулин А.А., Голочевская B.C. Прокинетики в лечении гастроэнтерологических заболеваний. //Клин, фармакол. тер. 1996. — Том 5, № 1 — С. 94−96.
- П.Шушапов С. С., Загрекова Е. И., Ермилова В. Д., Карамышева А. Ф. // Вестник ОНЦ. 1998. — № 4 — С. 6.
- AAPS Pharm Sci. 2002. — Vol. 4, № 4 — article 29.
- Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. / K. Naruhashi, I. Tamai, N. Inoue, et al. // J Pharm Pharmacol. 2001. — № 53. — P. 699−709.
- M.Alcamo IE. DNA Technology. Lond.: Harcourt Academic Press, 2001.
- Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra, Pastan I., Gottesman M.M.:Biochemical, cellutar and pharmacological aspects of the MDR transporter. // Ann Rev Pharmacol Toxicol 1999. — № 39. — P. 361−398.
- Amin A.S., Ragab G.H. Spectrophotometric methods for the determination of anti-emeic drugs in bulk and in pharmaceutical preparations.// Anal Sci. -2003 May. Vol. 19, № 5. — P. 747−751.
- Appenzeller T. Democratizing the DNA sequence. // Sceince. 1990. -Vol.247, № 4946. — P. 1030 — 1032.
- Argekar A.P., Shah S.J. Simultaneous determination of cinnarizine and domperidone maleate from tablet dosage form by reverse phase ion pair high perphomance liquid chromatography .//J Pharm Biomed Anal. 1999 May. -Vol. 19, № 6 — P. 813−817.
- C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. / M. Goto, S. Masuda, H. Saito et al // Pharmacogenetics. 2002. -Vol. 12, № 6. -P. 451−457.
- Cairo M., Siegel S., Anas N., Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine and continuous infusion VP-16 in drug-resistant pediatric tumors. // Cancer Res. 1987. — № 49. — P. 1063−1066.
- Characterization of human cytochrome P-450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. / B.A.Ward, A Morocho, A. Kandil et al. // Br J Clin Pharmacol. 2004, Sep — Vol. 58, № 3. — P. 277 287.
- Chen W, YangJ.Z., Andersen R, Nielsen L.H., Borchardt R.T. Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly
- Phe-D -Leu-OH DADLE., and its cyclic pro-drugs across the blood-brain barrier using an in situ perfused ratbrain model. // J Pharmacol Exp Ther. -2002. -№ 303. -P. 849−57.
- Chiou W.L., Chung S.M., Wu T.C. Apparent lack of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. // Pharm Res. 2000. — № 17. — P. 205−208.
- Chomczynski P, Saachi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. // Anal Biochem. -1987 Apr.-Vol. 162, № l.-P. 156−159.
- Cignitte M. et al. // Journal of Molecular Structure. 1995. — № 350, P. 4347
- Circumvention of vincristine and doxorubicin resistance in vitro and in vivo by calcium influx blokers. / T. Tsuruo, H. Iida, M. Norjiri, et al. // Cancer Res. 1983.- Vol. 434. — P.2905−2910.
- Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytara-bine. / G. Gerrard, E. Payne, R.J. Baker et al // Haematologica. 2004. -Vol. 89, № 7, P. 782−790.
- Cornwel M.M., Pastan I., Gottesman M.M. Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. // J. Biol. Chem. 1988. — № 262. — P. 7884−7888.
- Cummins L. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. // Clin Pharmacol Ther. -2002. № 75. — P. 56−67.
- Dc Lannoy LA. and Sirvcrman M: The MDR1 gene product P-glycoprotein mediates the transport of the cardiac glycoside digoxin. // Biochem Biophys ResCommun- 1992.-№ 189.-P. 331−337.
- Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. /Р. Song, S. Li, B. Meibohm et al. // AAPS PharmSci 2002. — Vol. 4, № 4. — E 29.
- Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar S. Evidence for two non-identical drug interaction sites in the human P-glycoprotein. // Proc Natl Acad Sci USA. 1997. — Vol. 94. № 10. — P. 594−599.
- Distribution of allelic variants of functional c3435t polymorphism of drug transporter MDRI gene in a sample of polish population. / K. Jamroziak, E. Balcerczak, W. MLYnarski et al // Pol. J. Pharmacol. 2002. — № 54. — P. 495−500.
- Distribution of domperidone into the rat brain is increased by brain ischae-mia or treatment with the P-glycoprotein inhibitor verapamil. / Y. Dan, H. Murakami, N. Koyabu et al // J. Pharm Pharmacol. 2002. — Vol. 54, № 5 -P. 729−733.
- Ескег G., Huber M., Schmid D., Chiba P. The importence of a nitrogen atom in modulators of MDR. // Mol Pharmacol 1999. — № 56 — P. 791−796.
- Effect of chronic administration of ritonavir on function of cytochrome P450 ЗА and P-glycoprotein in rats. / Kageyama M., Namiki H., Fukushima H., et al. // Biol Pharm Bull. -2005. -Vol. 28, № l.-P. 130−137.
- Erlich H. A., Gelfand D., Sninsky J. J. Recent advances in the polymerase chain reaction.// Science. 1991. — Vol. 252, № 5013. — P. 1643−1651.
- EUROGAPP Project 1999−2000. Genetic Tests Insurance and Employment: Technical, social and ethical issues. Background Document. 2000.
- Evans W.E., Johnson J. A. Pharmacogenomics: the inherited basis for inter-individual differences in drug response. // Annu Rev Genimics Hum Genet. -2001.-№ 2-P. 9−39.
- Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. // Science. 1999. — № 286 — P. 487−491.
- Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. / J. Hakkola, M. Pasanen, J. Hukkanen, et al. // Bio-chem.Pharmacol. 1996. — Vol. 51, № 4. — P. 403−411.
- Faassen F, Vogel G, Spanings H, Vromans H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. // Int J Pharm. 2003 Sep 16. — Vol. 263, № 1−2. — P. 113−22.
- Fricker, G., Miller, D.S. // Pharmacol. Toxicol. 2002. — 90(1), 5−13.
- Gao В., Stieger В., Noe В., Fritschy J. M., Meier P. J. // Journal of Histochemistry & Cytochemistry. 1999. — Vol. 47, № 10. — P.1255−1264.
- Georges EF., Sharom J., Ling V. Multidrug resistance and chemosensi-tization: therapeutic implications for cancer chemotherapy. // Adv. Pharmacol. Chemot-her. 1990. — № 21. — P. 185−220.
- Hashimoto Y, Sasa H, Shimomura M, Inui K. Effects of intestinal and hepatic metabolism on the bioavailability of ucrolimus in rats. // Pharm Res 1998. -№ 15. — P.1609−1613.
- Hashimoto Y., Sasa H., Shimomura M., Inui. K. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. // Pharm Res. -1998. Vol. 15, №Ю — P. 1609−1613.
- Higgins C.F. ABS transporters: from micro-organisms to man. // Ann. Rev. Cell. Biol. 1992. — № 8. — P. 67−71.
- Higgins CF, Gttesman MM. Is the multidrug transporter a flippase? // Trends Biochem Sci. 1992. — № 17. — P. 1821.
- Higuchi R., Fockler C., Dollinger G., Watson R. Kinetic PCR analysis: realtime monitoring of DNA amplification reactions // Biotechnology. — 1993. -Vol. 11, № 9.-P. 1026−1030.
- Human P-gtycoprotein transports Cortisol, aldosterone, and dexamethasone, but not progesterone. / K. Ueda, N. Okamura, M. Hirai et al. // J Biol Chem. -1992. Vol. 267. — P. 248−252.
- Identification of P-glycopotein substrates and ingibitors among psychoactive compounds implications for pharmacokinetics selected substrates. / El Ela A., Hartter S., Schmitt U., et al. // J. Pharm. Pharmacol. — 2004 Aug. -Vol.56-№ 8.-P.967−975.
- Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. / Kim RB, Wandel C, Leake В et al. // Pharm Res. 1999. — № 16.-P. 408−14.
- Iyer L., Ramirez J., Shepard D.R., Bingham C.M. Biliary transport of iri-notecan and metabolites in normal and P-glycoprotein-deficient mice. // Cancer Chmother Pharmaol. 2002. — № 49. — P. 336−341.
- J.D. Unadkat, A. Dahlin, S. Vijay. Placental Drug Transporters Current. // Drug Metabolism. 2004. — № 5 — P. 1127.
- Juliano R.L., Ling V. A. surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. // Biochem. Biophis. Acta. 1976. -№ 455.-P. 152−162.
- Kalow W., Tang B.K., Endrenyi I. Hypothesis: comparisons of inter- and in-tra-indiviual vaiations can substitute for twin studies in drug research. // Pharmacogenetics. 1998. — № 8. — P. 283−289.
- Kim R, Wilkinson G. Pharmacogenetics of drug transpoters. // Pharmacoge-nomics. -2001. P. 81−108.
- Kobylinska M., Kobylinska K. HPLC analysis for the determination of domperidone in human plasma. //J Chromatography B. 2000. — № 744. -P. 207−212.
- Kramer R., Weber Т.К., Arceci R. Inhibition of N-linked glycosylation of Pgp by tunicamycin results in a educed MDR phenotype. // Br J Cancer.1993.-№ 71. P. 670−676.
- Kuo SM, Whitby BR, Artursson P, Ziemniak JA. The contribution of intestinal secretion to the dose-dependent absorption of celiprolol. // Pharm Res.1994.-№ 11.-P. 648−53.
- Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. // Pharm. Rev. 2001 Dec. — Vol. 53, № 4. — P. 569−596,.
- Loo T.W., Bartlett M.C., Clark D.M. Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites. // J. Biol. Chem. 2003. — Vol. 278, № 50 — P.50 136−41 278.
- Loo T.W., Clarke D.M. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. // J. Biol. Chem. 2001. — Vol. 276, № 40. — P. 3 687 736 880.
- MacGrego E. A., Wilkinson M., Bancroft K. Domperidone plus paracetamol on the treatment of migraine. // Cephalgia. 1993. — № 13. — P. 124−127.
- Marzolini C., Paus E." Buclin T. Polymorphisms in human MDR1 (P-gp): Recent advances and clinical relevance. // Clin Pharmacol Ther. 2004. — № 75.-P. 13−33.
- McLeod H.L., Evans W.E. Pharmacogenomics: unlocking the human genome for better drug therapy. // Annu Rev Pharmcol Toxicol. 2001. — № 41.-P. 101−121.
- MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. K. Oselin, T. Gerloff, P.M. Mrozikiewicz, et al. // Fundam Clin Pharmacol. 2003. — Vol. 17, № 4.-P. 463−469.
- Meyer UA. Pharmacogenetics and adverse drug reactions. // Lancet. 2000. -№ 356.-P. 1667−1671.
- Mohamed ME, al-Khamees HA, al-Awadi M, al-Khamis KI. First-derivative UV spectrophotometric assay of domperidone.// Farmaco. 1989 Nov-44(ll): 1045−52.
- P-glycoprotein in the Blood-Brain Barrrier of mice influences the brain penetration and pharmacological activity of many drugs. // A. H Schinkel., Els Wagnaar et al. // J Clin Invest. June, 1996. — Vol. 97, № 11 — P. 2517−2524.
- P-glycoprotein-mediated transport of itracona/ole across the blood-brain barrier. / T. Miyama, H. Takanaga, H. Matsuo, et al. //Antimicrob Agents Chemother. 1998. — № 42. — P. 1738−1744.
- Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. / Huang YC, Colaizzi JL, Bierman RH, et al. // J Clin Pharmacol. -1986 Nov-Dec. Vol. 26, № 8. — P. 628−632.
- Pharmacological Inhibition of P- glycoprotein Transport Enhences the Distribution of HIV-1 Protease Inhibitors into Brain andtestes. / E. F. Choo, B. Leake, C. Wandel, et al // 2000 June. Vol. 28, Issue 6, P. 655−660.
- Phase 1 trial of etoposide with as cyclosporine as modulator multidrug resistance. / A.M.Yahanda, K.Mt. Adler, GA. Fisher, et al. // J. Clin.Oncol. 1992. — № 10 — P. 1624−1634.
- Pippert T.R., Umbenhauer D.R. The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdrla gene. // J Biochem Mol Toxicol. 2001. — № 15. — P. 83−89.
- Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. / G.R.Lankas, L.D.Wise, M.E.Cartwright, et al. // Reprod. Toxicol. 1998. — Vol. 12, № 4 — P. 457−463.
- Potention of domperidone-induced catalepcy by a P-glycoprotein ingibitor, cyclosporin A. / К Tsujikawa, Y Dan, К Nogawa et al. // Biopharm Drag Dispos. 2003, Apr — Vol 24, № 3 — P. 105−114.
- PriorT.I., Baker G.B.Interactions between the cytochrome P450 system and the second-generation antipsychotics. // J Psychiatry Neurosci. 2003. — № 28.-P. 99−112.
- Rao G.R., Kini G.R., Avadhanulu A.B., Vatsa D.K. Spectrophotometric estimation of acebutolol hydrochloride and domperidone in their dosage forms.//East.pharm. 1990. — Vol. 33. — P. 133−135.
- Rao G.R., Kini G.R., Avadhanulu A.B., Vatsa D.K. Spectrophotometric estimation of acebutolol hydrochloride and domperidone in their dosage forms. // East.pharm. may, 1990 — Vol. 33 — P133−135.
- Repid and sensitive liquid chromatography-tandem mass spectrometry method for the quantitation of domperidone in human plasma. / Smit M.J., Sutherland F.C., Hundt H.K.L., et al // J Chromatography A 2002 — Vol. 949-P. 65−70.
- Reversal of multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. /
- D.M.Woodcock, K. Lennartz, S. Jefferson, et al. // Cancer Res. 1990. -Vol. 50.-P. 4199−4203.
- Sadeque, Wandel, He, Shah, Wood, Clin Pharmacol Ther., 68, 231−9 (2000).
- Saeki T, Ueda K, Tanigawara Y, Hori R, Komamo T. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. // FEBS Left -1993,-Vol. 124.-P. 99−102.
- Sannerstedt R., Lundborg P., Danielsson B.R. Drugs during pregnancy: an issue of risk classification and information to prescribers. // Drug Saf. 1996. — Vol.14, № 2 — P 69−77.
- Schuett EG, Yasuda K, Arimnri K, Schuetz JD. Human MDR 1 and mouse mdrla P-glycoprotein alter the cellular retention and disposition of erythromycin, but not retinoic acid or benzo (a)pyrene. // Arch Biochem Bio-phys 1998. — Vol. 350. — P. 340−347.
- Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. // J Pharmacol Exp Ther. 1995. — Vol. 275. — P. 1011−1018.
- Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. // Annu. Rev. Pharmacol. Toxicol. -2003.-Vol.43-P. 285−307.
- Sekine, Т.- Cha, S. H. and Endou, H. Pflugers Archiv // European Journal of Physiologyro 2000. — Vol.440, № 3 — P. 337−50.
- Siegsmund M., Brinkmann U., Schaffeler E. et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. // J Am Soc Nephrol. -2002. Vol. 13, № 7 -P. 1847−1854 .
- Smit, J.W.- Huisman, M.T.- van Tellingen, O.- Wiltshire, H.R. and Schinkel, A.H. (1999) J. Clin. Invest., 104(10), 1441−1447.
- Sweet DH, Bush KT, Nigam SK. The organic anion transporter family: from physiology to ontogeny and the clinic. // Am J Physiol Renal Physiol. 2001, Aug. — Vol. 281, № 2. — P. 197−205.
- Tanabe M., Ieiri I., Nagata N., J. Pharmacol Exp Ther., 297(3), 113 743 (2001).
- Tartaglione T. A., Pieper J.A., Lopez L.L., Mehta J. Pharmacokinetics of verapamil and nonverapamil during long-term oral therapy. // Res. Commun. He-matol. Pathol. Pharmacol. 1983. — Vol. 40. — P. 1527.
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. / KB Kim, MF Fromm, С Wandel et al. //J Clin Invest. 1998. — № 10. — P. 289−294.
- The human mdrl gene: с DNA cloning and transcription initiation. / K. Ueda, D. Clark, C. Chen, et al // J. Biol. Chem. 1987. — Vol. 262. — P. 505−508.
- Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. / J. Erlich, C. N. Parry, C. F earns et al. // Proc Natl Acad Sci USA.- 1999, July 6. Vol. 96, № 14 — P. 81 388 143.
- Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human mdrl gene confers multidrug resistance to colchicines, doxorubicin and vinblastine. // Proc. Nat. Acad. Sci. USA. -1987.-Vol. 84.-P. 3004.
- Ulfelder K.J., Schwartz H.E., Hall J.M., Sunzeri FJ. Restriction fragment length polymorphism analysis of ERBB2 oncogene by capillary electrophoresis. // Anal. Biochem. 1992. — Vol. 200, № 2. — P. 260−267.
- Vesell E.S. Pharmacgenetic perspective gained from twin and family studies. // Pharmacol. Ther. 1989. — Vol. 41. — P. 535−552.
- Walle U.K., Walle T. Taxol transport by human intestinal epithelial Caco-2 cells. // Drug Metab Dispos. 1998. — Vol. 26. — P. 343−346.
- Williams, S. A.- Abbruscato, T. J.- Hruby, V. J. and Davis, T. P.(1996) J. Neurochem., 66(3), 1289−99.
- WoolfT.F. Handbook of drug metabolism. 1999. 153−169.
- Wu M.S., Gao L., Cai X.H., Wang G.J. Determination of domperi-done in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers.// Acta Pharmacol Sin. 2002. — Vol. 23 № 3. -P. 285−288.
- Wu Min-Shu, Gao Ling, CaiXiano-Hui, Wang Guuang-ji. Determination of domperidone in human plasma by LC-MS and its pharmacokinetics in healthy Chinese volunteers // Acta Pharmacol Sin. 2002. -Vol. 23, № 3 -P. 285−288.
- Yamamoto. K., Hagino M., Kotaki H., Iga T. Quantitative determination of domperidone in rat plasma by HPLC with fluorescence detection.// J Chromatography В 1998. — Vol. 720 — P.251−255.
- Zarabcar S.S., Salunkhe B.B. // Ind Drugs 27(10), 1990, P 537.